Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 241
- Registration Number
- NCT00829829
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00794417
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States
🇺🇸Kentucky Cancer Clinic, Hazard, Kentucky, United States
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 221
- Registration Number
- NCT00789477
Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT00609544
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00610363
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT00527423
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
- Conditions
- Interventions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2012-12-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1217
- Registration Number
- NCT00509795
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
- Conditions
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00383370
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 159
- Registration Number
- NCT00320788
- Locations
- 🇺🇸
Southeast Retina Center, Augusta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Charlotte Eye, Ear, Nose & Throat Asssociates, Charlotte, North Carolina, United States
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT00320814